Cadrenal Therapeutics to Hold Important Meetings at Healthcare Conference
PONTE VEDRA, Fla. — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a pioneering biopharmaceutical firm, is set to hold crucial partnering and investor meetings during the annual J.P. Morgan Healthcare Conference. This impactful event will take place across several days, allowing for valuable interaction with key stakeholders in the healthcare sector.
Engaging Directly with Partners and Investors
Quang X. Pham, CEO of Cadrenal Therapeutics, expressed enthusiasm about participating in this significant conference. He stated, "The events surrounding this prestigious conference provide a fantastic platform for Cadrenal to connect with both current and prospective partners. We aim to facilitate productive discussions about our strategic direction, including the acquisitions we made in 2025, which serve to elevate our mission of developing innovative anticoagulation solutions. These solutions are specifically designed to address critical gaps in managing rare and high-risk patient populations."
Innovative Pipeline Targeting a $40 Billion Market
Cadrenal Therapeutics is dedicated to filling voids in the expansive $40 billion anticoagulation market. Their diverse pipeline showcases a commitment to addressing unmet medical needs:
VLX-1005
This phase 2 candidate is a revolutionary parenteral 12-Lipoxygenase (12-LOX) inhibitor aimed at obstructing crucial mechanisms involved in immune-mediated platelet activation. It offers distinct advantages, such as blocking platelet activation and preventing thrombus formation. Furthermore, it holds Orphan Drug Designation (ODD) and fast track designation for treatment in patients suffering from heparin-induced thrombocytopenia (HIT).
Tecarfarin
Tecarfarin is a phase 3-ready oral Vitamin K antagonist (VKA) distinguished by its established mechanism of action, akin to warfarin, but with a notably improved metabolic pathway. This candidate also possesses ODD and fast track designation for patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib), as well as ODD for those utilizing left ventricular assist devices (LVADs) through a collaboration with Abbott Laboratories.
Frunexian
Frunexian represents a phase 2-ready acute parenteral Factor XIa (FXIa) inhibitor, unique for its fast-on/fast-off profile suitable for acute care scenarios. It targets patients undergoing complex cardiac surgery and those receiving continuous renal replacement therapy (CRRT).
Contacting Cadrenal Therapeutics
Interested parties are encouraged to reach out for partnering meetings at press@cadrenal.com. Investors seeking discussions can connect through Lytham Partners at cvkd@lythampartners.com.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc. dedicates its research and development efforts to advancing differentiated products that address significant needs in anticoagulation management, particularly for high-risk and rare patient demographics. Its portfolio includes VLX-1005, an industry-first Phase 2 12-LOX inhibitor; tecarfarin, an oral VKA for patients with chronic conditions; and frunexian, a potent parenteral small-molecule FXIa antagonist designed for acute hospital environments.
Frequently Asked Questions
What is the J.P. Morgan Healthcare Conference?
The J.P. Morgan Healthcare Conference is a leading annual event that brings together healthcare industry professionals, including investors, executives, and key stakeholders, to discuss developments and innovations.
What is the focus of Cadrenal Therapeutics?
Cadrenal Therapeutics focuses on developing advanced anticoagulation therapies that meet the needs of high-risk patient populations.
What products are in Cadrenal's pipeline?
Cadrenal's pipeline includes VLX-1005, tecarfarin, and frunexian, each targeting specific anticoagulation challenges.
How can investors engage with Cadrenal Therapeutics?
Investors can contact Cadrenal Therapeutics through Lytham Partners for meeting arrangements and discussions on investment opportunities.
What market does Cadrenal Therapeutics target?
Cadrenal Therapeutics is focused on the $40 billion anticoagulation market, addressing critical unmet needs.
